Carcinoid Syndrome Clinical Trial
Official title:
A Double Blind, Randomized Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome
The purpose of this study was to determine whether monthly deep subcutaneous (s.c.) injections of lanreotide Autogel (Somatuline Depot) were effective and safe in controlling diarrhoea and flushing by reducing the usage of s.c. short-acting octreotide as a rescue medication to control symptoms in subjects with carcinoid syndrome.
This study consisted of a Screening period, conducted up to 4 months before randomisation, followed by three phases: a 16-week, double blind (DB), randomised, placebo-controlled phase; a 32-week initial open label (IOL) phase; and a long term open label extension (LTOLE) phase. The DB phase evaluated lanreotide Autogel versus placebo in subjects with a history of carcinoid syndrome (flushing and/or diarrhoea). This was followed by a 32-week IOL phase in which all subjects received lanreotide Autogel 120 mg every 4 weeks. Subjects in countries where lanreotide Autogel had not been approved for the treatment of carcinoid syndrome, who were well-controlled at the end of the 32-week IOL phase and chose to continue to receive lanreotide Autogel, were given the option of participating in a LTOLE phase. The LTOLE phase of the study was planned to end at least 2 years after the last subject had completed his/her participation in the 32-week IOL phase or when marketing approval for the treatment of symptoms of carcinoid syndrome had been obtained in the respective countries (whichever occurred first) or at any time the study was terminated by the Sponsor. The actual overall duration of the study was 6.5 years. During the LTOLE phase all subjects continued to be treated with lanreotide Autogel 120 mg every 4 weeks. The study planned to enrol approximately 100 adult subjects worldwide. Screening continued until 115 subjects were enrolled in the study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04993261 -
An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors
|
Early Phase 1 | |
| Not yet recruiting |
NCT04039516 -
Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy
|
Phase 2 | |
| Completed |
NCT01234168 -
A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea
|
||
| Terminated |
NCT04073017 -
Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency
|
N/A | |
| Recruiting |
NCT05756608 -
Fibrosis in Chronic and Delayed Myocardial Infarction
|
||
| Withdrawn |
NCT04713202 -
Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl
|
Phase 2 | |
| Completed |
NCT00853047 -
Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
|
Phase 2 | |
| Completed |
NCT02063659 -
Telotristat Etiprate for Carcinoid Syndrome Therapy
|
Phase 3 | |
| Withdrawn |
NCT04776876 -
Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome
|
Phase 2 | |
| Completed |
NCT03223428 -
Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO
|
||
| Recruiting |
NCT03453489 -
AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm
|
Phase 2 | |
| Active, not recruiting |
NCT05361668 -
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
|
Phase 2 | |
| Completed |
NCT01104415 -
Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome
|
Phase 2 | |
| Withdrawn |
NCT01172717 -
Study of Panitumumab in the Treatment of Carcinoid Syndrome
|
Phase 2 | |
| Terminated |
NCT00884715 -
Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome
|
Phase 1/Phase 2 | |
| Completed |
NCT01677910 -
TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
|
Phase 3 | |
| Completed |
NCT01430871 -
Effects of Serotonin Excess on Bone in Carcinoid Syndrome
|
N/A | |
| Completed |
NCT02026063 -
Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
|
Phase 3 | |
| Terminated |
NCT01018953 -
Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome
|
Phase 2 | |
| Terminated |
NCT04140409 -
Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation
|
Phase 4 |